Homocysteine and the methotrexate toxicity in trisomy 21

Blatt J, Albo V, Prin W, Orlando S, Wollman M (1986) Excessive chemotherapy-related myelotoxicity in children with Down's syndrome and acute lymphoblastic leukemia. Lancet II: 914Google Scholar

Chadefaux B, Rethore MO, Raoul O, Ceballos I, Poissonnier M, Gilgenkrantz S, Allard D (1985) Cystathionine-beta-synthase: gene dosage effect in trisomy 21. Biochem Biophys Res Commun 128: 1–10Google Scholar

Chadefaux B, Ceballos I, Hamet M, Coude M, Poissonnier M, Kamoun P, Allard D (1988) Is absence of atheroma in Down's syndrome due to decreased homocysteine levels? Lancet II: 741Google Scholar

Frankel LS, Pullen J, Boyett J, Eastment C, Ragab A, Hvizdala E, Berry D, Sexaver C, Crist W, Vietti T (1986) Excessive drug toxicity in children with Down's syndrome (DS) treated for acute lymphatic leukemia (ALL) despite similarity of clinical and biological features of other patients. Proc Am Soc Clin Oncol 161 (5): 631Google Scholar

Garre ML, Relling MV, Kalwinsky D, Dodger R, Crom WR, Abromowitch M, Pui CH, Evans WE (1987) Pharmacokinetics and toxicity of methotrexate in children with Down's syndrome and acute lymphocytic leukemia. J Pediatr 111: 606–612Google Scholar

Lejeune J (1975) Réflexions sur la débilité de l'intelligence des enfants trisomiques 21. Pontif Accad Sci Acta 9: 11–12Google Scholar

Lejeune (1979) Investigations biochemiques et trisomie 21. Ann Genet 22: 67–75Google Scholar

Lejeune J (1990) On the pathogeny of mental deficiency in trisomy 21. Proceedings, international symposium on trisomy 21, Rome, May 21–24Google Scholar

Lejeune J, Rethore MO, Blois MC de, Maunoury-Burolla C, Mir M, Nicolle L, Borowy F, Borghi E, Recan D (1986) Metabolisme des monocarbones et trisomie 21: sensibilité au methotrexate. Ann Genet 29: 16–19Google Scholar

Peeters M, Lejeune J (1989) Beneficial effect of 6-mercaptopurine on the mitotic index of trisomy 21 lymphocytes. Ann Genet 32: 21–25Google Scholar

Peeters M, Lejeune J (1989) Methotrexate troxicity in Down's syndrome: investigation of thymidiylate synthetase and thymidine kinase pathways (abstract 4). Proceedings, international convention on Down's syndrome, Jerusalem, March 19–24, p 57Google Scholar

Peeters M, Poon A (1987) Down's syndrome and leukemia: unusual clinical aspects and unexpected methotrexate toxicity. Eur J Pediatr 146: 416–422Google Scholar

Peeters M, Poon A, Zipurski A, Olive D (1985) Mongolisme et leucemie: toxicité accrue du methotrexate. Proceedings, Congress, hematology and transfusion, Bordeaux, p 17Google Scholar

Peeters M, Poon A, Zipursky A, Lejeune J (1986) Toxicity of leukemia therapy in children with Down's syndrome. Lancet II: 1279Google Scholar

Peeters M, Rethore MO, Lejeune J (1989) In vitro sensitivity of trisomy 21 lymphocytes to chemotherapy: implication for future research (abstract). Proceedings, international symposium on trisomy 21, Rome, May 21–24Google Scholar

Skovby F, Krassikoff N, Francke U (1984) Assignment of the gene for cystathionine beta-synthase to human chromosome 21 in somatic cell hybrids. Hum Genet 65: 291–294Google Scholar

Ueland PM, Refsum H, Christensen B (1990) Methotrexate sensitivity in Down's syndrome: a hypothesis. Cancer Chemother Pharmacol 25: 384–386Google Scholar

Watkins SE, Clifford MA, Tidmarsh SF, Cowie VE, Shaw DM, AH-Sing E, Dickerson JW (1986) Plasma amino acids: Down's syndrome and dementia. Br J Psychiatr 148: 339–340Google Scholar